4.7 Article

ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS

Journal

CELL DEATH & DISEASE
Volume 5, Issue -, Pages -

Publisher

SPRINGERNATURE
DOI: 10.1038/cddis.2014.191

Keywords

ROCK2; LIMK1; axonal degeneration; regeneration; retinal ganglion cells; optic nerve crush

Categories

Funding

  1. Deutsche Forschungsgemeinschaft [LI 1308/3-1]
  2. Cluster of Excellence
  3. DFG Research Center Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Gottingen

Ask authors/readers for more resources

The Rho/ROCK/LIMK pathway is central for the mediation of repulsive environmental signals in the central nervous system. Several studies using pharmacological Rho-associated protein kinase (ROCK) inhibitors have shown positive effects on neurite regeneration and suggest additional pro-survival effects in neurons. However, as none of these drugs is completely target specific, it remains unclear how these effects are mediated and whether ROCK is really the most relevant target of the pathway. To answer these questions, we generated adeno-associated viral vectors to specifically downregulate ROCK2 and LIM domain kinase (LIMK)-1 in rat retinal ganglion cells (RGCs) in vitro and in vivo. We show here that specific knockdown of ROCK2 and LIMK1 equally enhanced neurite outgrowth of RGCs on inhibitory substrates and both induced substantial neuronal regeneration over distances of more than 5mm after rat optic nerve crush (ONC) in vivo. However, only knockdown of ROCK2 but not LIMK1 increased survival of RGCs after optic nerve axotomy. Moreover, knockdown of ROCK2 attenuated axonal degeneration of the proximal axon after ONC assessed by in vivo live imaging. Mechanistically, we demonstrate here that knockdown of ROCK2 resulted in decreased intraneuronal activity of calpain and caspase 3, whereas levels of pAkt and collapsin response mediator protein 2 and autophagic flux were increased. Taken together, our data characterize ROCK2 as a specific therapeutic target in neurodegenerative diseases and demonstrate new downstream effects of ROCK2 including axonal degeneration, apoptosis and autophagy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Clinical Neurology

Implications of dopaminergic medication withdrawal in Parkinson's disease

J. Koschel, K. Ray Chaudhuri, L. Toenges, M. Thiel, V Raeder, W. H. Jost

Summary: The trajectory of dopamine replacement therapy in treating Parkinson's disease is variable and dose adjustments may be necessary. Clear guidelines regarding tapering off PD medication are currently lacking, and sudden dose reductions could have serious consequences. Further research is needed to establish evidence-based recommendations on how to taper or discontinue medication for Parkinson's disease.

JOURNAL OF NEURAL TRANSMISSION (2022)

Review Clinical Neurology

Relevance of COMT inhibitors in the treatment of motor fluctuations

Wolfgang H. Jost, Carsten Buhmann, Joseph Classen, Karla Eggert, Zacharias Kohl, Tiago Outeiro, Lars Tonges, Dirk Woitalla, Heinz Reichmann

Summary: COMT inhibitors have been established for over 20 years in the treatment of motor fluctuations in Parkinson's disease. However, the available inhibitors differ in pharmacokinetics, indication requirements, and side effects, leading to many patients not receiving optimized drug treatment.

NERVENARZT (2022)

Article Clinical Neurology

Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies

Olivier Rascol, Lars Toenges, Tina DeVries, Mark Jaros, Adrian Quartel, David Jacobs

Summary: The study shows that IR/ER amantadine is effective in reducing LID, but the results vary in different doses and trials. However, despite some adverse events, it still has the potential to be an effective medication in the treatment of LID.

PARKINSONISM & RELATED DISORDERS (2022)

Article Neurosciences

L-DOPA administration shifts the stability-flexibility balance towards attentional capture by distractors during a visual search task

P. Riedel, I. M. Domachowska, Y. Lee, P. T. Neukam, L. Tonges, S. C. Li, T. Goschke, M. N. Smolka

Summary: The cognitive control dilemma refers to the balance between stability and flexibility in attention, which is believed to be maintained by dopamine. However, there is limited research on this balance in humans.

PSYCHOPHARMACOLOGY (2022)

Review Biochemistry & Molecular Biology

Update on CSF Biomarkers in Parkinson's Disease

Eun Hae Kwon, Sabrina Tennagels, Ralf Gold, Klaus Gerwert, Leon Beyer, Lars Toenges

Summary: This paper emphasizes the importance of reliable objective markers for identifying individuals at risk of Parkinson's disease. Advances in biomarker discovery, particularly in the cerebrospinal fluid (CSF), have provided promising preliminary results. Potential biomarkers include alpha-synuclein species, markers of amyloid and tau pathology, neurofilament light chain, lysosomal enzymes, and markers of neuroinflammation. Metabolomics approaches have also offered insights into novel biological pathways. Genetic forms of PD can help identify subgroups suitable for targeted treatments. Further validation studies are needed to determine the most valuable CSF biomarkers or combinations for clinical and research purposes.

BIOMOLECULES (2022)

Article Oncology

Multi-omic landscaping of human midbrains identifies disease-relevant molecular targets and pathways in advanced-stage Parkinson's disease

Lucas Caldi Gomes, Ana Galhoz, Gaurav Jain, Anna-Elisa Roser, Fabian Maass, Eleonora Carboni, Elisabeth Barski, Christof Lenz, Katja Lohmann, Christine Klein, Mathias Baehr, Andre Fischer, Michael P. Menden, Paul Lingor

Summary: This study investigated the molecular landscape of Parkinson's disease (PD) in human post-mortem midbrains and identified multiple molecular targets and networks that are relevant to the disease mechanism. The findings suggest that neuroinflammation, immune response activation, mitochondrial dysfunction, and defects in synaptic function could be potential therapeutic targets for advanced PD.

CLINICAL AND TRANSLATIONAL MEDICINE (2022)

Article Clinical Neurology

Adenosine A2A Receptor Antagonists as a Treatment Option for Parkinson's Disease?

Wolfgang H. Jost, Lars Toenges

Summary: In Parkinson's disease, the focus has traditionally been on motor symptoms and dopaminergic therapy. However, the importance of non-motor symptoms has gained recognition, highlighting the need for treatment of non-dopaminergic deficits. Adenosine A (2A) receptor antagonists have been identified as an additional therapy, as they can modulate the striato-thalamo-cortical loops.

FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE (2022)

Review Biochemistry & Molecular Biology

The Role of Axonal Transport in Glaucoma

Mariana Santana Dias, Xiaoyue Luo, Vinicius Toledo Ribas, Hilda Petrs-Silva, Jan Christoph Koch

Summary: Glaucoma is a neurodegenerative disease that leads to progressive vision loss by affecting the retinal ganglion cells (RGCs). Impairment of axonal transport at the optic nerve head (ONH) is an important feature of glaucoma, and is believed to occur early in the disease before axonal and somal degeneration. Understanding the role of axonal transport in glaucoma is crucial for deciphering disease mechanisms and developing early therapies to prevent irreversible neuronal damage.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Clinical Neurology

Best practice approaches to outpatient management of people living with Parkinson's disease during the COVID-19 pandemic

Antonia F. Demleitner, Andreas W. Wolff, Johanna Erber, Friedemann Gebhardt, Erica Westenberg, Andrea S. Winkler, Susanne Kolbe-Busch, Iris F. Chaberny, Paul Lingor

Summary: Parkinson's disease (PD) is a common neurodegenerative disease with a rising prevalence. Infection with SARS-CoV-2 can lead to a complicated disease course for PD patients. Currently, there is a lack of guidelines for managing outpatient PD patients during times of increased infection risk. However, measures such as mask-wearing, hand hygiene, social distancing, and appropriate testing strategies can minimize exposure risk. Telemedicine consultations can be used for low urgency visits, while in-person presentation is required for moderate and high urgency visits. Vaccination against SARS-CoV-2 is safe and effective for PD patients, playing a key role in reducing infection risk.

JOURNAL OF NEURAL TRANSMISSION (2022)

Letter Clinical Neurology

A Novel NPTX1 de novo Variant in a Late-Onset Ataxia Patient

Jonas Deppe, Natalie Deininger, Paul Lingor, Tobias B. Haack, Bernhard Haslinger, Marcus Deschauer

MOVEMENT DISORDERS (2022)

Article Immunology

Mild COVID-19 imprints a long-term inflammatory eicosanoid-and chemokine memory in monocyte-derived macrophages

Sina Bohnacker, Franziska Hartung, Fiona Henkel, Alessandro Quaranta, Johan Kolmert, Alina Priller, Minhaz Ud-Dean, Johanna Giglberger, Luisa M. Kugler, Lisa Pechtold, Sarah Yazici, Antonie Lechner, Johanna Erber, Ulrike Protzer, Paul Lingor, Percy Knolle, Adam M. Chaker, Carsten B. Schmidt-Weber, Craig E. Wheelock, Julia Esser-von Bieren

Summary: SARS-CoV-2 infection leaves an inflammatory imprint in MDM, resulting in aberrant macrophage function and eicosanoid metabolism, leading to long-term immune aberrations in patients recovering from mild COVID-19.

MUCOSAL IMMUNOLOGY (2022)

Article Neurosciences

Impact of the COVID-19 Pandemic on Patients with Parkinson's Disease from the Perspective of Treating Physicians-A Nationwide Cross-Sectional Study

Andreas Wolfgang Wolff, Bernhard Haller, Antonia Franziska Demleitner, Erica Westenberg, Paul Lingor

Summary: The COVID-19 pandemic has had a significant impact on the medical care of patients with Parkinson's disease, leading to worsening symptoms, appointment cancellations, and difficulties in organizing treatments. Physicians offered alternative consultation options, with telephone consultations being the most accepted by patients.

BRAIN SCIENCES (2022)

Article Clinical Neurology

Data-driven subtyping of Parkinson's disease: comparison of current methodologies and application to the Bochum PNS cohort

Qiang Chen, Raphael Scherbaum, Ralf Gold, Kalliopi Pitarokoili, Axel Mosig, Samis Zella, Lars Toenges

Summary: A data-driven clustering analysis was conducted to identify three subtypes of Parkinson's disease: early onset mild type, intermediate type, and late-onset severe type. The Parkinson's Disease Questionnaire (PDQ-39), Non-motor Symptom Questionnaire (NMSQuest), and the MDS-UPDRS Part II were found to be crucial factors for differentiating PD subtypes.

JOURNAL OF NEURAL TRANSMISSION (2023)

Article Cell Biology

Synchrotron-Based Fourier-Transform Infrared Micro-Spectroscopy of Cerebrospinal Fluid from Amyotrophic Lateral Sclerosis Patients Reveals a Unique Biomolecular Profile

Tanja Ducic, Jan Christoph Koch

Summary: By analyzing the cerebrospinal fluid (CSF) of ALS patients using FTIR spectroscopy, this study reveals significant changes in the molecular contents, including RNA, glutamate, carbohydrates, and key markers of lipid metabolism. These findings suggest that FTIR characterization of CSF could be a powerful tool for ALS diagnosis and provide insights into the pathophysiology of ALS.

CELLS (2023)

Article Biochemistry & Molecular Biology

Quality Control-A Stepchild in Quantitative Proteomics: A Case Study for the Human CSF Proteome

Svitlana Rozanova, Julian Uszkoreit, Karin Schork, Bettina Serschnitzki, Martin Eisenacher, Lars Toenges, Katalin Barkovits-Boeddinghaus, Katrin Marcus

Summary: Proteomic studies using mass spectrometry (MS)-based quantification are important for discovering new biomarkers, but the accuracy of the outcomes can be affected by various analytical conditions. Therefore, it is crucial to assess the quality of the acquired data, including raw data, identification, and quantification levels. This study demonstrates the assessment of four independent datasets from cerebrospinal fluid, highlighting the impact of sample processing-based differences on the quality of quantitative data. Additionally, a free and open source quality control tool called MaCProQC is provided for systematic and rapid data comparison.

BIOMOLECULES (2023)

No Data Available